Vir Biotechnology Inc (VIR) NPV
2.06%- This stock can be held in a
Stocks and Shares ISA
$0.15
(2.84%)$0.15
(2.84%)Company Information
About this company
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Key people
Key facts
- EPICVIR
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS92764N1028
- Market cap$784.46m
- Employees408
- Shares in issue137.14m
- ExchangeNASDAQ
- IndexS&P 600 Small Cap, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.